CClinicalTrials.gg
CompletedNCT07562555Updated May 1, 2026

Bioactive Materials in Vital Pulp Therapy of Permanent Teeth

An interventional study of Direct pulp capping with ProRoot MTA and Direct pulp capping with BIOfactor MTA in Vital Pulp Therapy, sponsored by Ege University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 13 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Ege University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Jan 2025, registered Apr 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
13 Years to 65 Years
Sex
All
01

Study summary

This randomized clinical study aimed to evaluate and compare the clinical, radiographic, and postoperative pain outcomes of direct pulp capping performed using two calcium silicate-based materials: ProRoot MTA and Biofactor MTA in permanent teeth with vital pulp exposure.

A total of 80 teeth were randomly allocated into two groups according to the capping material used. Following standardized caries removal and achievement of hemostasis, direct pulp capping was performed using either ProRoot MTA or Biofactor MTA under similar clinical conditions. Definitive coronal restorations were completed 24 hours after the procedure.

Postoperative pain was assessed using a numerical rating scale (NRS) at 0, 6, 12, 24, and 48 hours after treatment. Patients were instructed to record their pain levels and analgesic intake during this period.

Patients were recalled for clinical and radiographic evaluations at 6 and 12 months. Clinical success was defined as the absence of spontaneous pain, sensitivity, swelling, sinus tract formation, and tenderness to percussion or palpation. Radiographic success was determined by the absence of periapical pathology.

Additionally, the influence of demographic and clinical variables, including age, gender, characteristics of pulp exposure, and intraoperative factors, on treatment outcomes and pulpal healing was evaluated.

Read the detailed description

This randomized controlled clinical study was designed to evaluate and compare the clinical performance, radiographic outcomes, postoperative pain, and pulpal healing following direct pulp capping using two calcium silicate-based materials: ProRoot MTA and Biofactor MTA in permanent teeth with vital pulp exposure.

A total of 80 teeth diagnosed with vital pulp requiring direct pulp capping were included in the study. Participants were randomly allocated into two equal groups (n=40) according to the pulp capping material used. All procedures were carried out under standardized clinical conditions.

Caries removal was performed using a sterile round diamond bur under water cooling, followed by excavation with a spoon excavator. Teeth with pulp exposure were included in the study. Hemostasis was achieved. In cases where bleeding could not be controlled within a clinically acceptable time, the tooth was excluded from the study.

In the experimental group, Biofactor MTA was applied directly over the exposed pulp tissue according to the manufacturer's instructions. In the control group, ProRoot MTA was used following the same protocol. After placement of the capping material, a protective base was applied, and the cavity was temporarily restored. Definitive coronal restorations were completed 24 hours after the initial procedure.

Postoperative pain was evaluated using a Numerical Rating Scale (NRS) at 0, 6, 12, 24, and 48 hours following treatment. Patients were instructed to record their pain intensity and the number of analgesic tablets taken during this period.

Patients were recalled for follow-up examinations at 6 and 12 months. Clinical evaluation included assessment of spontaneous pain, sensitivity, swelling, sinus tract formation, tenderness to percussion and palpation, and periodontal probing depths. Radiographic evaluation was performed to assess the presence of periapical pathology.

Treatment success was defined as the absence of clinical symptoms and the absence of radiographic signs of pathology.

Furthermore, the influence of demographic and clinical variables, including age, gender, number and location of pulp exposures, size of exposure, and bleeding control time, on treatment outcomes was analyzed.

02

Conditions studied

  • Vital Pulp Therapy

Keywords

  • dental pulp
  • bioactive material
  • direct pulp capping
  • endodontics
03

In context

Lead sponsor

Ege University is the lead sponsor of 365 studies on the registry; 46 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
13 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Patients aged between 13 and 65 years
  • Patients with adequate patient-clinician communication
  • Patients who agree to attend periodic follow-up visits throughout the study
  • Patients who provide written informed consent to participate in the study
  • Systemically healthy patients
  • Teeth with no previous endodontic treatment
  • Teeth showing a positive response to cold and electric pulp test
  • Permanent teeth
  • Posterior teeth
  • Teeth that can be restored with direct composite restoration
  • Teeth with pulp exposure (pulpal perforation)
  • Presence of bleeding from the exposed pulp that can be controlled within 5-10 minutes

Exclusion criteria

Exclusion Criteria:

  • Patients who refuse to participate in the study
  • Medically compromised patients (e.g., patients with systemic diseases, immunological disorders, or those using medications)
  • Patients with known allergies to materials used during vital pulp therapy
  • Pregnant patients
  • Non-vital teeth
  • Presence of advanced periodontal disease (probing depth > 3 mm)
  • Teeth with previous endodontic treatment
  • Teeth with insufficient remaining tooth structure that cannot be restored with restorative materials
  • Teeth where adequate isolation cannot be achieved
  • Teeth requiring post core restoration
  • Patients in whom periapical radiographs cannot be obtained
  • Patients unable to attend follow-up visits
  • Cases in which bleeding from the exposed pulp cannot be controlled within 5-10 minutes
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Active comparator
    ProRoot MTA

    In this group, direct pulp capping procedures were performed using ProRoot MTA. Following caries removal under water cooling with a sterile round diamond bur and spoon excavator, teeth with pulp exposure were included in the study. Hemostasis was achieved. ProRoot MTA was then placed directly over the exposed pulp tissue according to the manufacturer's instructions. A protective base was applied over the material, and the cavity was temporarily restored. Definitive coronal restoration was completed 24 hours after the procedure.

    Procedure: Direct pulp capping with ProRoot MTA

  • Experimental
    BIOfactor MTA

    In this group, direct pulp capping procedures were performed using BIOfactor MTA. Following caries removal under water cooling with a sterile round diamond bur and spoon excavator, teeth with pulp exposure were included in the study. Hemostasis was achieved. BIOfactor MTA was placed over the exposure site in accordance with the manufacturer's recommendations. A protective base material was applied, and temporary restoration was performed. Permanent coronal restoration was completed 24 hours later.

    Procedure: Direct pulp capping with BIOfactor MTA

Interventions

  • ProcedureDirect pulp capping with ProRoot MTA

    Direct pulp capping was performed using ProRoot MTA after caries removal and hemostasis. The material was placed over the pulp exposure, and definitive restoration was completed after 24 hours.

  • ProcedureDirect pulp capping with BIOfactor MTA

    Direct pulp capping was performed using Biofactor MTA following caries removal and hemostasis. The material was applied directly over the exposed pulp, and definitive restoration was completed after 24 hours.

06

What researchers measure

Primary outcomes

  1. Clinical and radiographic success of direct pulp capping

    Treatment success defined as the absence of clinical symptoms, including spontaneous pain, sensitivity, swelling, sinus tract formation, and tenderness to percussion or palpation, together with the absence of radiographic signs of pathology such as periapical radiolucency.

    Time frame: 1 year follow-up

Secondary outcomes

  1. Postoperative pain intensity following direct pulp capping

    Postoperative pain will be evaluated using a Numerical Rating Scale (NRS), where patients rate their pain intensity at predefined time intervals after treatment. The Numerical Rating Scale is a pain measurement scale that encompasses the following grades: 0 no pain, 1-3 mild pain, 4-6 moderate pain, 7-10 severe pain. Patients will be instructed to record their pain levels and analgesic intake.

    Time frame: up to 2-day

07

Study locations

1 site
  • Ege University Faculty of Dentistry
    Izmir, 35100, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07562555
Lead sponsor
Ege University
Responsible party
Gözde Kandemir Demirci (Principal Investigator, Ege University) — Principal investigator
First posted
May 1, 2026
Start date
Jan 10, 2025
Primary completion
Apr 10, 2026
Completion
Apr 10, 2026
Last update
May 1, 2026

Study contacts

Gözde Kandemir Demirci, Associate Professor
principal investigator · Ege University Faculty of Dentistry

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion